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Abstract
Metastatic disease is the main cause of death in patients with colorectal cancer and the
most frequent location of metastases is in the liver. The treatment of liver metastases of
colorectal  origin  is  multimodal  and  should  be  based  on  a  multidisciplinary  team
decision.  A  systematic  review  of  the  literature  revealed  that  the  number  of  liver
metastases, their maximum size, CEA level, advanced age of the patients, and presence
of extrahepatic disease are no longer contraindications to liver resection. The resecta‐
bility rate of colorectal liver metastases increased from 10 to almost 40%, enabling 5‐
year overall survival rates higher than 30%. Short‐term and long‐term results achieved
by simultaneous resection (SR) are similar to those achieved by staged resections in
patients  with  synchronous  colorectal  liver  metastases.  Whenever  possible,  major
hepatectomies should be replaced by ultrasound‐guided limited liver resections, and
primary tumor should be approached in a minimally invasive manner. Even initially
unresectable colorectal liver metastases could be rendered resectable by an aggressive
multimodal  approach  (“two‐stage”  hepatectomies,  hepatectomy  after  portal  vein
embolization/ligation,  resection  after  conversion  chemotherapy,  and  hepatectomy
associated  with  ablation).  The  presence  of  extrahepatic  metastases  is  no  longer  a
contraindication to  liver  resection,  when extrahepatic  disease  is  resectable.  Repeat
hepatectomy improves survival in patients with recurrent liver metastases.
Keywords: colorectal liver metastases, liver resection, survival, liver re‐resection, un‐
resectable liver metastases
1. Introduction
Colorectal cancer is the third cause of cancer‐related death among adult patients [1]. Most of
the patients with colorectal carcinoma decease due to the metastatic disease, and only a small
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percentage of these patients die due to the complications of the primary tumor or other
comorbidities. Thus, in order to increase the life expectancy of patients with colorectal cancer,
it is mandatory to improve the therapeutic strategies addressed to the metastatic colorectal
cancer (mCRC). Because more than two thirds of the patients with colorectal cancer will
develop liver metastases during their lifetime, it is obvious that the improvements in the
treatment of liver metastases will translate into higher survival rates for these patients [2].
In this chapter, the current therapeutic strategies and the potential future trends in the onco‐
surgical treatment of colorectal liver metastases (CLMs) are presented.
2. Treatment of liver metastases from colorectal cancer
Nowadays, the treatment of colorectal liver metastases is multimodal, including liver resection,
ablative therapies, chemotherapy, targeted therapies, and interventional radiology (radioem‐
bolization, chemoembolization, and portal vein embolization).
The most recent studies revealed that the highest survival rates have been achieved by
complete resection of CLMs. Thus, an international database including more than 25,000
patients treated for CLMs (collected from 313 centers all over the world) revealed that the 5‐
year overall survival (OS) rate achieved by liver resection was 42%, while the 5‐year overall
survival rate achieved by ablative therapies was 26% (p value < 0.001). Moreover, the 5‐year
overall survival rate achieved by nonsurgical therapies was only 6% (p value < 0.001) [3].
2.1. Pretherapeutic evaluation
The main objectives of pretherapeutic evaluation are as follows: (1) confirmation of the
presence of liver metastases, (2) assessment of extrahepatic metastases, and (3) evaluation of
liver metastases resectability.
2.1.1. Confirmation of liver metastases
The presence of metastatic disease should be determined in all the patients diagnosed with
colorectal cancer, at the time of their primary tumor diagnosis. The metastases identified at
that time are considered as synchronous metastases, as well as the metastases detected during
the operation addressed to the primary tumor (even when they were not revealed by preop‐
erative evaluation). However, patients without synchronous metastases who underwent a
curative‐intent resection of the colorectal primary tumor should be periodically followed‐up
because up to 50% of them will develop metastases of colorectal origin [4]. These metastases
are considered as metachronous colorectal metastases.
The evaluation performed to diagnose metastases from colorectal cancer is based on the CT
scan of the thorax, abdomen, and pelvis. Sometimes, when the CT scan cannot rule out the
presence of liver metastases, magnetic resonance imaging (MRI) could be useful because its
specificity is higher than that of CT scan.
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2.1.2. Assessment of extrahepatic metastases
When the presence of extrahepatic disease is suspected, PET/CT should be performed in order
to achieve a correct pretherapeutic evaluation. Moreover, in the past few years, the NCCN and
ESMO guidelines suggested a routine performance of PET/CT scan in patients with resectable
CLMs, to assess the extension of the disease [5].
Whenever the patient shows signs or symptoms suggestive for brain metastases, a head CT
scan should be performed; similarly, when bone metastases are suspected, a bone scintigraphy
is mandatory.
2.1.3. Evaluation of liver metastases resectability
The paradigm regarding the CLMs resectability has changed over the past two decades. Thus,
in the early 1990s, the following situations were considered as contraindications for liver
metastases resection: (a) the presence of more than four CLMs, (b) the size of liver metastases
exceeding 5 cm of maximum diameter, (c) the presence of extrahepatic metastases, and (d) the
advanced age of the patient (usually older than 70 years). During the past few years, one by
one, each of these contraindications has been challenged by the results reported by different
authors, based on smaller or larger cohorts of patients undergoing liver resection for CLMs
exceeding these criteria.
At present, the largest database including patients with CLMs who underwent surgery with
the intention of curative resection is LiverMetSurvey—an international registry of patients
operated in 313 centers from 70 countries [3]. According to the report released by the managers
of this database in December 2015, important observations regarding the usefulness of liver
resection in different groups of patients were presented.
a. Although the survival rates achieved in patients with up to 3 CLMs were statistically
significant, higher than those reported in patients with 4 or more CLMs, even in patients
with more than 7 CLMs, the 5‐year overall survival (OS) rate (achieved by curative‐intent
hepatectomy) was 26% [3]. These results suggested that the number of CLMs should not
represent a contraindication to liver resection.
b. Regarding the size of CLMs, although the highest survival rates were achieved in the
group of patients with liver metastases lower than 3 cm, the 5‐year OS rates were higher
than 35% also in patients with CLMs larger than 5 cm [3].
c. In patients with synchronous hepatic and extrahepatic metastases who underwent
curative‐intent surgery for both liver metastases and extrahepatic metastases, the 5‐year
OS rate was 22%, significantly lower than those achieved in patients with liver‐only
metastases (5‐year OS rate—44%). However, the 22% survival rate in 5 years is obviously
higher than the survival rates achieved by palliative treatment in patients with mCRC (6%
rate in 5 years according to the same database) [3]. Thus, the presence of concomitant
extrahepatic disease is no longer considered as a contraindication to surgery, when the
entire metastatic burden could be resected.
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d. Because the life expectancy increased significantly in most countries, more and more
elderly patients, with a good clinical status, were diagnosed with CLMs. The results
presented by the LiverMetSurvey database revealed that in patients older than 70 years,
the 5‐year OS rate was 38% [3]. Thus, curative‐intent hepatectomy is a worthwhile
operation even in elderly patients and the age should not be considered as a contraindi‐
cation for liver resection if the patient’s performance status is good.
Because almost all the traditional contraindications to liver resection are no longer valid
nowadays, the definition of the CLMs resectability should be based on a technical/practical
point of view, taking into account what remains after liver resection.
At present, technical criteria of resectability include the anticipated ability to [6]
1. perform a margin‐negative resection (R0);
2. preserve at least two contiguous liver segments with adequate vascular inflow, outflow,
and biliary drainage;
3. preserve adequate future liver remnant (FLR) volume (at least 20–30% of functional liver
volume in patients with normal liver and 30–35% of functional liver volume in patients
pretreated with chemotherapy).
Moreover, in patients with a marginal FLR volume and/or underlying liver disease, the ability
of FLR to function effectively should be assessed (frequently based on the appropriate
regenerative response after portal vein embolization – PVE) [6].
Based on these criteria, the indications of liver resection for CLMs broadened over the past two
decades, providing increased resectability rates in patients with CLMs. Thus, at present, it is
considered that among the patients newly diagnosed with CLMs, almost 25% are initially
resectable, whereas 75% are initially unresectable metastases.
Regarding the potentiality to resect CLMs, ESMO classified the patients with liver metastases
in four groups [7]:
Group 0: Primarily, technically R0‐resectable liver metastases and no “biological” relative
contraindications (e.g., progressive disease during neo‐adjuvant treatment, etc.).
Group 1: Potentially resectable metastatic disease with curative intention.
Group 2: Disseminated disease, technically “never”/unlikely resectable.
Group 3: Never‐resectable metastatic disease.
2.2. Initially resectable CLMs: Group 0
Regarding the onco‐surgical approach to CLMs, there are some differences between patients
presenting synchronous CLMs (SCLMs) and patients who develop metachronous CLMs
(MCLMs). These different strategies should mainly take into account the concomitant presence
of the primary tumor and liver metastases in patients with SCLMs and the need to remove
both tumor locations.
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2.2.1. Synchronous colorectal liver metastases
The first approach used in patients with SCLMs is consisted of two stages. During the first
stage, the resection of the primary tumor is performed; and subsequently, usually 2–3 months
later, the resection of liver metastases is performed. This strategy is called delayed liver
resection (DR) and theoretically presents a few advantages as presented below.
Due to the progress made in liver surgery and anesthesiology, in the late 1990s some centers
started to perform, in selected patients, simultaneous resection of the primary tumor and liver
metastases. The advantages postulated by the promoters of this simultaneous resection
approach (SR) include the comfort of the patient (who avoids two surgical procedures under
general anesthesia), the avoidance of progression to unresectability of CLMs (which is possible
in the DR approach, during the interval between the two operations), and it is cost‐effective [8–
10].
However, the partisans of the DR approach advocate that this strategy is based on two
theoretical assumptions: (a) DR avoids the association of two resections, thus reduces the risks
of postoperative complications and mortality, and increases the safety of the procedure; (b) the
biological behavior of the tumor could be assessed during the observation period between the
two operations, thus allowing a better selection of the patients and improving the oncologic
outcome [11, 12].
2.2.1.1. Safety of the procedure
Although the SR was looked upon with caution during the first few years after its launch, the
results reported over the past two decades revealed that in patients with colon tumors and
liver metastases requiring minor hepatectomies, the morbidity and mortality rates achieved
by SR were similar to those observed in patients undergoing DR [13–16].
However, if the primary tumor is complicated with perforation or obstruction, due to the poor
clinical condition of the patient, it is advisable to avoid the simultaneous resection and this
situation is considered a common reason for DR.
In patients with rectal tumors and/or requiring major hepatectomies, the SR is still controver‐
sial because some authors reported significantly higher morbidity and mortality rates after SR
in such instances than those shown by DR [16]. By these reasons, a consensus conference on
CLMs management suggested caution in performing SR in such patients and recommended
a staged approach (either delayed liver resection or liver‐first approach) [17].
The liver-first approach is a new surgical strategy that consists of initial resection of liver
metastases and subsequent resection of the primary tumor [18]. This approach is recommend‐
ed especially in patients with border‐line resectable CLMs (Figure 1) and/or rectal cancers. The
advantages of this new approach over the classical delayed liver resection are as follows:
‐ When CLMs are border‐line resectable at the time of the diagnosis, if a DR is scheduled, there
is a major risk of metastases progression after the primary tumor resection, making the
metastases unresectable and missing the chance of a potentially curative resection. This
scenario could be avoided by the initial removal of CLMs. Because, in such situations, the
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complete resection of metastases usually requires a major hepatectomy (Figure 2), it is
recommended to avoid the performance of a simultaneous resection in order to decrease the
postoperative morbidity and mortality rates. Thus, the resection of the primary tumor could
usually be postponed for few weeks, with a low risk of developing primary tumor complica‐
tions.
‐ Moreover, if the primary tumor involves the rectum, in order to decrease the risk of local
recurrence, it is advisable to perform preoperative radiotherapy. Because during radiotherapy
the patient does not receive Oxaliplatin or Irinotecan and the interval between the start of
radiotherapy and the time of rectal resection is usually longer than 3 months, the risk of CLMs
progression to unresectability is high. Thus, the initial resection of CLMs avoids their pro‐
gression to unresectability and allows the optimal treatment of the primary tumor, offering
the highest chance of survival to these patients (Figure 3).
Figure 1. Abdominal CT scan of a 73‐year‐old patient with middle rectal adenocarcinoma and synchronous multiple
liver metastases [5]: (a) segments 3 and 1 (caudate lobe) liver metastases; (b) the caudate lobe metastasis is adjacent to
the inferior vena cava (IVC) and encases the middle hepatic vein; (c) segment 4 metastasis; (d) segment 6 metastasis; (e)
segment 8 metastasis.
Updates in Liver Cancer120
Figure 2. Liver-first approach (left hepatectomy extended to segment 1 and metastasectomies for the segment 6 and 8
CLMs): (a) specimen of left hepatectomy extended to segment 1, depicting the segment 1 metastasis with encasement
of the middle hepatic vein; (b) the same specimen with segment 3 and 4 metastases; (c) specimens of metastasectomies
for segment 6 and 8 CLMs; (d and e) intraoperative images of the remnant liver after complete resection of CLMs.
Figure 3. Specimen of low anterior rectal resection performed after short-course radiotherapy (the patient underwent
radiotherapy after liver-first resection): (a) the specimen of low anterior rectal resection with total mesorectal excision;
(b) the same specimen, transected (at least 2 cm distal resection margin).
2.2.1.2. Oncologic outcome
Regarding the postulated advantages offered by the “observation period,” most of the series
published until now revealed that the overall survival rates achieved by SR were similar to
those achieved by staged resections [8, 13, 19]. Thus, the speculated advantage of “better
selection of patients by DR” does not seem to be supported by the practice. This could be
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explained by the fact that most patients underwent chemotherapy between the two operations,
and in the era of modern chemotherapy the progression‐free survival rates are longer than 6
months [20]. Thus, the information provided by the “test of time” between the two operations
is mitigated by the chemotherapy.
Moreover, a recent retrospective study, based on the results observed in patients enrolled in
LiverMetSurvey, revealed that in patients with synchronous CLMs, the preoperative chemo‐
therapy did not improve overall survival [21].
In conclusion, at present, most authors recommend the following approaches:
• Simultaneous resection (SR) in patients with uncomplicated colon tumors and synchronous
CLMs requiring minor hepatectomies.
• Delayed resection (DR) in patients with obstruction or perforation of the primary tumor and
synchronous CLMs.
• Liver‐first approach in patients with border‐line resectable CLMs (requiring major hepa‐
tectomies) and/or rectal carcinoma
2.2.2. Metachronous colorectal liver metastases
In patients with initially resectable metachronous CLMs, the up‐front surgery could be
recommended.
Preoperative chemotherapy may be useful especially in patients with a high clinical risk score
(CRS). The clinical risk score is calculated by assigning one point to each of the following
factors: multiple CLMs, metastases diameter larger than 5 cm, CEA level higher than 200
U/ml, node‐positive status of primary tumor (pathological), and disease‐free interval less than
12 months [22]. A recent study revealed that neo‐adjuvant chemotherapy significantly
improved the survival rate in patients with a high clinical risk score (CRS 3–5), whereas in
patients with a low risk profile (CRS 0–2) neo‐adjuvant chemotherapy might not be beneficial
[23].
However, the postoperative (adjuvant) chemotherapy is universally recommended at present,
being considered almost mandatory after resection of CLMs, irrespective of the time of their
appearance (synchronous or metachronous). The goals of postoperative chemotherapy are to
increase both the disease‐free survival (DFS) and overall survival (OS) rates [5].
2.3. Potentially resectable CLMs: Group 1
In this group, those patients who cannot undergo a complete resection of CLMs at the time of
diagnosis, but are resectable by applying several onco‐surgical strategies are included.
Thus, the goal of the treatment in this group should be conversion to resectability.
The following strategies will be able to render resectable the initially unresectable CLMs:
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2.3.1. Liver resection following portal vein embolization or ligation
When the complete resection of CLMs would leave in place at least two adjacent liver segments,
but the FLR volume is not large enough to avoid the risk of postoperative liver failure, it might
be possible to enlarge the volume of the FLR by performing portal vein ligation (PVL) or
embolization (PVE) [24–26].
This strategy is especially useful in patients presenting CLMs confined to the right hemiliver
and segment 4. In such instances, frequently the volume of segments 2 and 3 is lower than 25–
30% of functional liver volume (FLV). The right portal branch ligation or embolization could
induce the hypertrophy of segments 2–3 (FLR), thus ensuring a volume of the FLR higher than
25–30% of FLV in 2–8 weeks after the procedure [24, 27]. The same therapeutic approach could
be applied in patients with CLMs confined to the right hemiliver and presenting a small left
hemiliver (the volume of segments 2–4 is lower than 25–30% of the FLV).
The occlusion of the right portal branch will induce the atrophy of the right hemiliver and
compensatory hypertrophy of the left hemiliver [28]. Thus, the ratio of FLR hypertrophy
regularly ranges between 20 and 50% and the volume of segments 2 and 3 (or of the left
hemiliver) will often exceed 25–30% of the FLV [24, 27, 29, 30]. Consequently, a right trisectio‐
nectomy or right hepatectomy could be safely performed in more than 60% of the patients
undergoing PVE/PVL, achieving the 5‐year overall survival rates higher than 30% [24, 27, 30,
31].
The evaluation of FLR and FLV is usually based on software‐assisted image postprocessing
programs that provide volume measurements taking into account the actual anatomy of a
specific patient (identified by CT scan), where FLV = volume of the entire liver – volume of the
tumor. FLR represents the volume of the segments that are planned to be left in place after the
scheduled curative liver resection.
Unfortunately, in almost one third of these patients, the complete resection of the metastatic
disease could not be achieved, either due to the insufficient hypertrophy of the FLR or due to
the development of new metastases in the FLR during the interval between PVL/PVE and the
scheduled hepatectomy [24, 27, 32].
In order to overcome these drawbacks of portal vein occlusion, recently, a new strategy has
been launched, aiming to increase the resectability rates in such patients.
2.3.2. ALPPS (associating liver partition and portal vein ligation for staged hepatectomy)
This surgical approach consists of association of the right portal branch ligation with transec‐
tion of liver parenchyma during the same operative procedure. It was observed that this
strategy enables a more rapid and greater hypertrophy of the FLR [33–35]. Thus, 7–10 days
after this operation, the percentage of FLR volume hypertrophy ranges between 40 and 80%
[33, 35], allowing the subsequent performance of R0 resection in almost 90–100% of the patients
subjected to this new approach [36, 37].
Onco-Surgical Management of Liver Metastases from Colorectal Cancer
http://dx.doi.org/10.5772/65223
123
Moreover, it was proved that in patients who failed to achieve adequate FLR hypertrophy after
PVE, the performance of ALPPS was effective, inducing a FLR gain that allowed subsequent
R0 resection [37, 38].
Because the hypertrophy of the FLR produced by ALPPS is 11‐fold faster than those induced
by PVL/PVE [34], this new strategy allows the complete resection of the tumor in a shorter
period of time (7–14 days after the first stage), providing additional advantages, such as: (1)
decreases the risk of disease progression between the two stages of the operation [36, 39]; (2)
allows a more rapid recovery of the patient, decreasing the length of hospital stay [36]; and (3)
the adjuvant chemotherapy could be started sooner than in patients undergoing PVL/PVE [36].
The main disadvantage of ALPPS is the high rate of major postoperative complications (27–
41%) and mortality (8–12.5%) [34, 35, 37, 40, 41]. To decrease the morbidity and mortality rates,
some authors recommended avoiding the performance of ALPPS in patients older than 60
years and to circumvent the ligation of the right bile duct during the first operation [34, 40–
42]. Other factors associated with a dismal outcome are obesity, poststage one biliary fistula,
and infected/bilious peritoneal fluid at the time of the second‐stage operation [37].
However, a thorough selection of patients and a meticulous surgical technique could overcome
these drawbacks, allowing the complete resection of initially unresectable CLMs in most
patients scheduled for this approach.
2.3.3. Two-stage liver resection
This strategy is mainly recommended in patients presenting multiple bilobar CLMs, whose
resection is not feasible during a single operative procedure because the volume of the remnant
liver would be too small to avoid the postoperative liver failure [28, 43, 44]. Thus, the goal of
complete resection of CLMs could be achieved by combining two liver resections. During the
first operation, the liver metastases from the FLR (usually left hemiliver or segments 2–3) are
resected by metastasectomies, sparing as much as possible of the remnant functional liver.
Consequently, the second‐stage operation aims at the complete removal of CLMs, frequently
by a right hepatectomy or a right trisectionectomy [28, 43, 44].
Because the volume of the FLR is commonly insufficient (due to the liver resections already
performed during the first operation), PVL could be carried out in the first stage. If the PVL
was not performed during the first operation and the CT scan evaluation made before the
second stage would reveal an insufficient volume of the FLR, a PVE could be underwent before
the second surgery. Therefore, the hypertrophy of the FLR achieved by portal vein occlusion
will allow the safe performance of the second operation, avoiding the risk of postoperative
liver failure.
In the series reported until now, the resectability rates achieved by this approach ranged
between 60 and 80%, and the 3‐year overall survival (OS) rates were higher than 35% [28, 43–
45].
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2.3.4. Liver resection after downsizing chemotherapy
This onco‐surgical approach is usually performed in patients with few large metastases, whose
initial resection would not preserve an adequate volume of the remnant liver parenchyma [28,
46, 47]. The goal of the treatment is to achieve the shrinkage of the tumors to such an extent
that makes possible their resection.
In such patients with potentially resectable CLMs (Group 1), it is recommended to start an
intense chemotherapy regimen, usually consisting of three chemotherapic drugs (5‐FU,
Oxaliplatin, and Irinotecan—FOLFOXIRI) and a monoclonal antibody [5]. In patients with
RAS‐wild‐type tumors the use of an anti‐EGFR (epidermal growth factor receptor) monoclonal
antibody (Cetuximab or Panitumumab) is recommended, whereas in patients with RAS‐
mutant tumors the use of anti‐VEGF (vascular endothelial growth factor) agent (Bevacizumab)
is advocated.
The response to the treatment should be assessed every 2 months after the therapy commences
(by CT scan or MRI) and the patient should be referred to the surgery as soon as the metastases
became resectable. The continuation of the oncologic therapy beyond this time point could
expose the patient to three dangerous scenarios:
‐ After the initial response to the oncologic therapy, the metastases could regrow, closing the
“window of opportunity” for liver resection. Thus, the patient misses the chance of a poten‐
tially curative liver resection due to the useless continuation of chemotherapy [28].
‐ Due to the hepatic toxicity of both Oxaliplatin and Irinotecan, there is a high risk of an
impaired liver function secondary to the long‐course chemotherapy (usually more than six
cycles) [48–50]. Oxaliplatin induces vascular disorders causing the appearance of the so‐called
“blue‐liver,” whereas Irinotecan induces steatohepatitis (NASH—nonalcoholic steatohepati‐
tis) that generates the so‐called “yellow‐liver” [48–50]. When liver resection is performed in
such patients, the morbidity and mortality rates increase dramatically, especially when major
hepatectomies are needed [51–53]. Thus, to avoid the higher postoperative morbidity and
mortality rates in patients whose CLMs were rendered to resectability after downsizing
chemotherapy is mandatory to perform liver resection as soon as the metastases became
resectable. Moreover, data derived from the LiverMetSurvey database revealed that the higher
the number of chemotherapy cycles or lines, the lower the survival after liver resection [3].
‐ If the chemotherapy is prolonged too much, some liver metastases could become unidenti‐
fiable on CT scan or MRI. Unfortunately, this clinical/radiologic complete response is not
equivalent to pathologic complete response, and it was well established that in more than 80%
of cases the viable tumor cells are still present at the site of initial liver metastases (although
they could not be found radiologically or intraoperatively) [54]. These lesions are called
“vanishing metastases” and their initial sites should be resected in order to avoid their
recurrence. However, this goal is difficult, especially when the metastases were originally
located deep in the liver parenchyma. The metastases that could not be resected because they
are not identified intraoperatively are called “missing metastases.” In such instances, it is
recommended to have a close follow‐up of the patients in order to identify, as soon as possible,
the “reappearance” of CLMs and perform their resection. In patients with “missing metasta‐
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ses,” intra‐arterial chemotherapy could also be offered which seems to decrease the recurrence
rates [55].
By using 5‐FU and Oxaliplatin, the Paul Brousse group reported a rate of conversion to
resectability of 13% [49, 56], whereas more recent series reported even higher conversion rates
(up to 28%) by using intense chemotherapy regimens associated with targeted therapies [57].
In patients who underwent curative‐intent resection of initially unresectable CLMs downsized
by chemotherapy, the disease‐free survival (DFS) and overall survival (OS) rates were statis‐
tically significant lower than those achieved in patients undergoing R0 resection for initially
resectable CLMs [28, 56]. However, the 5‐year OS rates (higher than 25%) achieved by patients
rendered to resectability after chemotherapy are statistically significant, higher than those
reported in patients who received only palliative oncologic treatment (6% at 5 years) [3, 56].
These results justify the efforts to render the resectability of the initially unresectable CLMs by
conversion chemotherapy [28].
Moreover, early tumor shrinkage (the decrease of CLMs size with more than 20%, according
to RECIST criteria, after 8 weeks of treatment) induced by the combination of chemotherapy
with anti‐EGFR agents (Cetuximab or Panitumumab) correlates with a higher rate of conver‐
sion to resectability [58, 59]. Meanwhile, early tumor shrinkage is a strong predictor of
favorable outcome, both in patients undergoing liver resection and in patients whose CLMs
could not be rendered to resectability [59, 60]. In patients who experienced early tumor
shrinkage and underwent curative‐intent liver resection, the 5‐year OS rates were statistically
significant, higher than those reported in patients rendered to resectability but who did not
experience early tumor shrinkage [59].
2.3.5. Liver resection associated with ablative treatment
This strategy aims at the complete clearance of the liver and is especially recommended in
patients with multiple bilobar CLMs that cannot be completely resected.
The ablative therapies are represented by radiofrequency ablation (RFA), microwave ablation
and cryosurgery. The most widely used ablative therapy is RFA and most studies revealed that
the local recurrence rates after RFA of CLMs smaller than 3 cm are similar to those achieved
by liver resection [61].
For this reason, in patients with multiple bilobar CLMs the resection of the bulk metastatic
burden (usually by a major hepatectomy—right hepatectomy or right trisectionectomy) and
RFA of the small liver metastases from the remnant liver could be performed.
This approach is also of particular interest in patients with multiple CLMs, one of which is ill‐
located (e.g., in the proximity of hepato‐caval confluence or portal vein bifurcation). Usually,
the resection of such ill‐located metastasis requires the removal of a large volume of normal
liver parenchyma, increasing the risk of postoperative liver failure. Performing RFA for that
metastasis avoids a major hepatectomy, sparing a large volume of nontumoral liver paren‐
chyma, without compromising the oncologic outcome. In such instances, all the liver meta‐
stases could be resected, except for the ill‐located one, which can be treated by ablation.
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This strategy (also called CARe—combined ablation and resection) has recently gained wide
acceptance because current studies [62] revealed that the long‐term outcomes achieved by
CARe (5‐year OS rates up to 37%) are similar to those achieved by the other strategies used to
render the resectability of the initially unresectable CLMs. Thus, the DFS and OS rates achieved
by this approach are similar to those achieved by “two‐stage” hepatectomies in the setting of
multiple bilobar CLMs [63]. Moreover, the morbidity and mortality rates after CARe tend to
be lower than those reported after “two‐stage” liver resections [63].
However, these favorable long‐term outcomes cannot be achieved if the diameter of the
metastasis that will be ablated is larger than 3 cm or if the tumor is not completely ablated.
2.4. Disseminated disease, technically “never”/unlikely resectable: Group 2
In this group of patients, the therapeutic intention is rather palliative [5] and, obviously, the
medical oncologist should start the treatment. According to the ESMO guidelines, the prefer‐
red option for the first line therapy is a cytotoxic doublet in combination with a targeted agent
[5]. For symptomatic patients with RAS‐wild type tumors, the association of FOLFOX/FOLFIRI
with an anti‐EGFR agent (Cetuximab or Panitumumab) seems to be the preferred therapy,
whereas in the other patients the association of a cytotoxic doublet with Bevacizumab should
be proposed.
When imaging re‐evaluation shows evidence of favorable response of CLMs to the first‐line
treatment, the therapy should be reconsidered based on a multidisciplinary team decision.
Thus, if liver metastases became resectable, the patient should be referred to surgery. Even
when CLMs were not rendered to resectability, oligometastatic patients could benefit from
ablative therapies. In this situation, the ablation of the metastases could be performed percu‐
taneously by an interventional radiologist. Although the DFS rates are lower than those
achieved by liver resection, this approach could offer a period of chemotherapy discontinua‐
tion until the disease progresses [5].
In patients who did not become eligible for surgery or ablation, the de‐escalation of the initial
combination should be considered [5], in order to achieve a prolonged progression‐free
interval with good symptom control and, eventually, a higher overall survival rate.
2.5. Never-resectable metastatic disease: Group 3
This group includes the patients with bulk metastatic burden (frequently hepatic and extra‐
hepatic) who cannot be rendered to resectability by anyone of the above‐mentioned strategies.
The goal of the treatment should be the prevention of tumor progression as long as possible
and the prolongation of life with minimal treatment load [5], without aiming maximal tumor
shrinkage because conversion to resectability was ruled out ab initio. These goals might be
achieved by either of the two approaches: (1) cytotoxic doublet (FOLFOX or FOLFIRI) usually
associated with a monoclonal antibody, shifting to the other doublet on progression; (2)
escalation strategy, starting with a fluoropyrimidine drug frequently associated with Bevaci‐
zumab, followed (on progression) by a cytotoxic doublet associated with a targeted agent [5].
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At present, the interventional oncology techniques (e.g., selective internal radiation therapy,
SIRT, and chemoembolization using drug‐eluting beads Irinotecan, DEBIRI) are usually used
in the second or the third‐line therapy, but their efficacy is still under evaluation.
Table 1. Algorithm for onco‐surgical management of patients with synchronous CLMs.
A meta‐analysis revealed that DEBIRI achieved higher progression free survival (PFS) rates
and better quality of life than standard oncologic therapy, when used in the second or the third‐
line treatment (after disease progression on previous lines of systemic chemotherapy) [64].
Moreover, a randomized controlled trial compared the results of FOLFOX+Bevacizumab ver‐
sus FOLFOX+DEBIRI+Bevacizumab in the first‐line treatment of patients with initially unre‐
sectable CLMs. It was observed that the combination of FOLFOX, DEBIRI, and Bevacizumab
achieved higher response rates, higher resectability rates, and significantly higher PFS rates
than the standard combination of FOLFOX with Bevacizumab [65].
Thus, it is possible that future studies will establish a more prominent role for these therapies
in the treatment of patients with initially unresectable CLMs.
In conclusion, the algorithm for onco‐surgical management of CLMs is presented in Table 1
(synchronous CLMs) and Table 2 (metachronous CLMs).
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Table 2. Algorithm for onco‐surgical management of patients with metachronous CLMs.
2.6. Technical issues in surgery of CLMs
During the past decade, the classical paradigms regarding the minimal resection margins that
should be achieved, the adequate type of liver resection and the modality of surgical approach
to liver metastases and primary tumor have been challenged by recent advances in surgery,
anesthesiology, and medical oncology.
2.6.1. Resection margins
The classical paradigm regarding the width of resection margins postulated that a minimum
margin of 10 mm is mandatory, to avoid the local recurrence. Later on, it was revealed that even
narrower resection margins could be accepted if the metastasis is located in close proximity of
bilio‐vascular structures that should be preserved. Thus, Tanaka et al. reported a local recur‐
rence rate of 2.8% in patients who underwent resection of CLMs with margins ranging between
2 and 4 mm and no local recurrence when resection margins were wider than 4 mm [66].
Therefore, at present, the resection of CLMs is recommended whenever a negative resection
margin (R0) could be achieved [6].
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Moreover, recent papers have revealed that in patients who primarily underwent R1 resection
(CLMs located in contact with intrahepatic vascular structures that should be preserved) and
subsequently modern postoperative chemotherapy, the overall survival rates were similar to
those observed in patients who underwent R0 resections ( p value > 0.05) [67, 68].
2.6.2. Types of liver resections
In the late 1990s, it was considered that anatomical liver resections offer superior long-term
outcomes than nonanatomical hepatectomies because the rate of positive resection margins
would be higher when nonanatomical resections were performed [69]. Later on, most authors
revealed that the survival rates were similar irrespective of the type of liver resection, as long
as complete resection (R0) of liver metastases could be achieved [22, 70].
Moreover, a considerable disadvantage of anatomical resections is related to the higher volume
of nontumoral liver parenchyma that is removed, especially when major hepatectomies are
performed. This issue has a negative impact on both the short-term and long-term outcomes.
For example, a large retrospective study revealed that the number of liver segments resected
and blood loss were the only predictors for both postoperative morbidity and mortality [71].
The authors concluded that reductions in the number of resected liver segments and blood
loss are primarily responsible for the decrease in the perioperative mortality rate [71]. More-
over, because the recurrence rate of CLMs after an initial complete resection is up to 66% [72,
73] and the highest survival rates in patients with recurrent CLMs are achieved by liver re-
resections [74–76], it is obvious that a parenchyma-sparing hepatectomy should be always
performed, in order to increase the possibility of subsequent liver resections.
Consequently, whenever possible, major liver resections should be replaced by parenchyma-
sparing hepatectomies in order to decrease the perioperative morbidity and mortality rates
and to offer the chance of repeat hepatectomies in patients with recurrent CLMs, thus pro-
longing their survival. For these reasons, at present, most authors recommend the performance
of (ultrasound-guided) limited liver resections in patients with CLMs instead of major
anatomical hepatectomies [72, 77, 78].
2.6.3. Surgical approach
At present, laparoscopic colorectal resection offers similar morbidity, mortality, and survival
rates as open resection of colorectal cancers [79]. Moreover, the laparoscopic approach decreases
the blood loss, and ensures a more rapid postoperative recovery and shorter hospital stay [80].
By these reasons, in patients with synchronous CLMs, it is recommended to perform laparo-
scopic resection of the primary tumor and resection of liver metastases by an open approach,
either during the same operative time (simultaneous resection) or as a staged procedure (delayed
liver resection or liver-first resection). The simultaneous performance of colorectal resection by
laparoscopy and liver resection by the open approach is particularly useful in patients presenting
left colon or rectal tumor and liver metastases located in the right hemiliver [80].
Due to the technological progress made in the past few years, the rectal tumors have been
approached more frequently by robotic surgery, and the morbidity, mortality, and survival
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rates are similar to those achieved by laparoscopic or open approach [81]. Because the
anatomical structures of the pelvis are better visualized during robotic procedures, we
recommend, in patients with rectal cancer and synchronous CLMs, the robotic resection of the
primary tumor and resection of liver metastases by open surgery [82].
The progresses in laparoscopy also allowed the performance of liver resection by this approach.
A meta‐analysis revealed that laparoscopic liver resections enable lower blood loss and shorter
hospital stay than open hepatectomies [83]. Moreover, a retrospective study reported a lower
morbidity rate after laparoscopic hepatectomies than in patients undergoing liver resection by
open approach [84]. Both of the above mentioned papers revealed that in patients undergoing
laparoscopic liver resections for malignant diseases, the rates of complete resection (R0) were
similar to those achieved in patients undergoing open hepatectomies [83, 84]. Regarding the
long‐term results achieved by laparoscopic resection of malignant liver tumors, the survival
rates were similar to those achieved by open surgery [85–88]. Based on these outcomes, in the
last period, in experienced centers, laparoscopic resection of CLMs is more frequently
performed, even in patients scheduled for simultaneous resection of the primary tumor and
liver metastases [82, 89, 90].
2.7. Recurrent CLMs
Almost two thirds of patients who underwent complete resection (R0) of CLMs will develop
recurrent metastases, most of them during the first three years after the initial resection [72,
73]. The same therapeutic modalities are available to treat the recurrent CLMs and the highest
survival rates are achieved by repeat liver resection [74–76, 91–93]. In the past few years, an
increasing number of patients underwent a third, fourth, or even more liver resection and the
available data suggest that the higher the number of repeated liver resections, the higher the
survival rates [3, 75, 93]. Thus, the repeat liver resection is one of the most important therapeutic
tools that contribute to a significant prolongation of overall survival in patients with CLMs.
Regarding the technical aspects, repeat liver resections presents some peculiar features, which
could increase the risk of intraoperative and postoperative complications:
‐ Due to the previous liver resection, most patients develop perihepatic adhesions, thus
increasing the risk of visceral (stomach, duodenum, and colon) or vascular (portal vein, inferior
vena cava) injuries.
‐ The liver parenchyma is frailer as a consequence of the liver regeneration process (after the
previous liver resection) and due to the hepatotoxicity induced by the prior chemotherapy.
Thus, the amount of blood loss during the repeat liver resection could be higher than through
the first hepatectomy, increasing the risk of postoperative complications.
‐ Because a part of the functional liver parenchyma has already been resected and previous
chemotherapy could induce steatohepatitis or intrahepatic vascular injuries, the risk of
postoperative liver failure after repeat hepatectomies is higher than after the first operation.
To avoid this potentially fatal postoperative complication, it is advisable to perform paren‐
chyma sparing hepatectomies both at the time of primary liver resection and during the
subsequent hepatectomies.
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However, recent studies revealed that the morbidity and mortality rates after liver re‐resection
are not statistically significant, higher than those induced by the first operation [91].
2.8. Surgery in patients with hepatic and extrahepatic colorectal metastases
Although the presence of extrahepatic metastases was considered a major contraindication to
liver resection for CLMs, the data presented during the last decade revealed that liver resection
might be beneficial even in the presence of extrahepatic disease, when the entire metastatic
burden could be resected [94, 95]. However, the performance of FDG‐PET is mandatory prior
to surgery, to assess the complete extent of metastatic disease.
Obviously, the survival rates are lower than those achieved in patients presenting liver‐only
colorectal metastases, but the 5‐year overall survival rates up to 22% achieved in patients with
concomitant extrahepatic disease seem to justify the efforts to accomplish the complete
resection of metastatic disease [59].
The resection of the entire metastatic burden could be achieved during a single operation (liver
resection associated with resection of intra‐abdominal metastases – e.g., hepatic pedicle lymph
nodes metastases, ovarian metastases, peritoneal metastases, adrenal metastases, etc.) or by
staged operations (e.g., initial resection of liver metastases, followed by resection of lung
metastases in a second stage).
In patients presenting hepatic and peritoneal metastases, along with liver resection, cytore‐
ductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC)
should be offered, in order to achieve the highest survival rates [96, 97].
The favorable prognostic factors seem to be up to five liver metastases, extrahepatic disease
confined only to the lung, primary tumor located on the left colon, and the CEA level lower
than 10 ng/ml [98].
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